Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.

Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP.

Oncologist. 2019 May 31. pii: theoncologist.2019-0331. doi: 10.1634/theoncologist.2019-0331. [Epub ahead of print]

PMID:
31152080
2.

The use of 3'-deoxy-3'-18F-fluorothymidine (FLT) PET in the assessment of long-term survival in breast cancer patients treated with neoadjuvant chemotherapy.

Ueberroth BE, Lawhorn-Crews JM, Heilbrun LK, Smith DW, Akoury J, Ali-Fehmi R, Eiseler NT, Shields AF.

Ann Nucl Med. 2019 Jun;33(6):383-393. doi: 10.1007/s12149-019-01345-w. Epub 2019 Feb 27.

PMID:
30810980
3.

Perioperative and oncological outcomes of abdominoperineal resection in the prone position vs the classic lithotomy position: A systematic review with meta-analysis.

Mesquita-Neto JWB, Mouzaihem H, Macedo FIB, Heilbrun LK, Weaver DW, Kim S.

J Surg Oncol. 2019 Jun;119(7):979-986. doi: 10.1002/jso.25402. Epub 2019 Feb 6.

PMID:
30729542
4.

The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer.

Dyson G, Farran B, Bolton S, Craig DB, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun LK, Bock CH.

Am J Cancer Res. 2018 Oct 1;8(10):2088-2095. eCollection 2018.

5.

Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer.

Heath EI, Heilbrun LK, Smith D, Schopperle WM, Ju Y, Bolton S, Ahmed Q, Sakr WA.

Anticancer Res. 2018 Nov;38(11):6361-6366. doi: 10.21873/anticanres.12994.

PMID:
30396958
6.

Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer.

Vaishampayan UN, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, Dobson KC, Boerner J, Stark K, Smith DW, Heath EI, Fontana JA, Shields AF.

Clin Cancer Res. 2019 Jan 15;25(2):652-662. doi: 10.1158/1078-0432.CCR-18-1473. Epub 2018 Oct 16.

PMID:
30327304
7.

Dynamical features in fetal and postnatal zinc-copper metabolic cycles predict the emergence of autism spectrum disorder.

Curtin P, Austin C, Curtin A, Gennings C, Arora M; (for the Emergent Dynamical Systems Group), Tammimies K, Willfors C, Berggren S, Siper P, Rai D, Meyering K, Kolevzon A, Mollon J, David AS, Lewis G, Zammit S, Heilbrun L, Palmer RF, Wright RO, Bölte S, Reichenberg A.

Sci Adv. 2018 May 30;4(5):eaat1293. doi: 10.1126/sciadv.aat1293. eCollection 2018 May.

8.

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.

Sanai N, Li J, Boerner J, Stark K, Wu J, Kim S, Derogatis A, Mehta S, Dhruv HD, Heilbrun LK, Berens ME, LoRusso PM.

Clin Cancer Res. 2018 Aug 15;24(16):3820-3828. doi: 10.1158/1078-0432.CCR-17-3348. Epub 2018 May 24.

9.

Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.

Thakur MK, Heilbrun L, Dobson K, Boerner J, Stark K, Li J, Smith D, Heath E, Fontana J, Vaishampayan U.

Clin Genitourin Cancer. 2018 Jun;16(3):e695-e703. doi: 10.1016/j.clgc.2018.01.019. Epub 2018 Feb 13.

10.

A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.

Farran B, Dyson G, Craig D, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun L, Bolton S, Bock CH.

Carcinogenesis. 2018 Apr 5;39(4):556-561. doi: 10.1093/carcin/bgy025.

PMID:
29471417
12.

Oxidative Stress Challenge Uncovers Trichloroacetaldehyde Hydrate-Induced Mitoplasticity in Autistic and Control Lymphoblastoid Cell Lines.

Frye RE, Rose S, Wynne R, Bennuri SC, Blossom S, Gilbert KM, Heilbrun L, Palmer RF.

Sci Rep. 2017 Jun 30;7(1):4478. doi: 10.1038/s41598-017-04821-3.

13.

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.

Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL, Piekarz RL, Sukari AW, Chao J, Pilat MJ, Smith DW, Casetta L, Boerner SA, Chen A, Lenkiewicz E, Malasi S, LoRusso PM.

Oncotarget. 2017 May 16;8(20):32918-32929. doi: 10.18632/oncotarget.16464.

14.

A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [18F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer.

Vaishampayan UN, Tehrani OS, Lawhorn-Crews JM, Heilbrun LK, Dobson K, Smith D, Dickow B, Shields AF.

Mol Imaging Biol. 2017 Dec;19(6):810-816. doi: 10.1007/s11307-017-1057-y.

PMID:
28289967
15.

Phase II Trial of Dose-dense Pemetrexed, Gemcitabine, and Bevacizumab in Patients With Advanced, Non-Small-cell Lung Cancer.

Schneider BJ, Kalemkerian GP, Gadgeel SM, Valdivieso M, Hackstock DM, Chen W, Heilbrun LK, Ruckdeschel JC, Wozniak AJ.

Clin Lung Cancer. 2017 May;18(3):299-302. doi: 10.1016/j.cllc.2016.11.019. Epub 2016 Dec 2.

PMID:
28063799
16.

Outcomes of nonsurgical management of locally advanced carcinomas of the sinonasal cavity.

Chopra S, Kamdar DP, Cohen DS, Heilbrun LK, Smith D, Kim H, Lin HS, Jacobs JR, Yoo G.

Laryngoscope. 2017 Apr;127(4):855-861. doi: 10.1002/lary.26228. Epub 2016 Nov 15.

17.

The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II.

Nakajima K, Heilbrun LK, Smith D, Hogan V, Raz A, Heath E.

Oncotarget. 2017 Mar 14;8(11):17643-17650. doi: 10.18632/oncotarget.12620.

18.

Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.

Nakajima K, Heilbrun LK, Hogan V, Smith D, Heath E, Raz A.

Oncotarget. 2016 Dec 13;7(50):82266-82272. doi: 10.18632/oncotarget.12619.

19.

Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients.

Hwang C, Sethi S, Heilbrun LK, Gupta NS, Chitale DA, Sakr WA, Menon M, Peabody JO, Smith DW, Sarkar FH, Heath EI.

Am J Transl Res. 2016 Jan 15;8(1):166-76. eCollection 2016.

20.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3.

21.

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, Smith D, Heath EI.

Invest New Drugs. 2016 Feb;34(1):112-8. doi: 10.1007/s10637-015-0307-6. Epub 2015 Nov 18.

PMID:
26581400
22.

Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.

Vaishampayan U, Shevrin D, Stein M, Heilbrun L, Land S, Stark K, Li J, Dickow B, Heath E, Smith D, Fontana J.

Urology. 2015 Dec;86(6):1206-11. doi: 10.1016/j.urology.2015.08.008. Epub 2015 Sep 12.

PMID:
26375845
23.

Organic Compounds Detected in Deciduous Teeth: A Replication Study from Children with Autism in Two Samples.

Palmer RF, Heilbrun L, Camann D, Yau A, Schultz S, Elisco V, Tapia B, Garza N, Miller C.

J Environ Public Health. 2015;2015:862414. doi: 10.1155/2015/862414. Epub 2015 Jul 29.

24.

Maternal Chemical and Drug Intolerances: Potential Risk Factors for Autism and Attention Deficit Hyperactivity Disorder (ADHD).

Heilbrun LP, Palmer RF, Jaen CR, Svoboda MD, Perkins J, Miller CS.

J Am Board Fam Med. 2015 Jul-Aug;28(4):461-70. doi: 10.3122/jabfm.2015.04.140192.

25.

Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck.

Sukari A, Al-Hajeili M, Salem M, Heilbrun L, Smith D, Yoo G, Jacobs JR, Lin HS, Kucuk O.

Avicenna J Med. 2015 Apr-Jun;5(2):36-41. doi: 10.4103/2231-0770.154195.

26.

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.

PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.

27.

Sample size determination for logistic regression on a logit-normal distribution.

Kim S, Heath E, Heilbrun L.

Stat Methods Med Res. 2017 Jun;26(3):1237-1247. doi: 10.1177/0962280215572407. Epub 2015 Mar 4.

28.

PET scans as a predictive marker of survival in advanced colorectal cancer.

Choi M, Kollepara SL, Heilbrun LK, Smith D, Shields AF, Philip PA.

Clin Colorectal Cancer. 2015 Mar;14(1):35-40. doi: 10.1016/j.clcc.2014.10.001. Epub 2014 Oct 23.

29.

Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men.

Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1505-11. doi: 10.1158/1055-9965.EPI-13-1328. Epub 2014 May 6.

30.

Erratum: Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.

Kong D, Heath E, Chen W, Cher M, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr W, Menon M, Sarkar F.

Am J Transl Res. 2013 Dec 1;6(1):102-103. eCollection 2013.

31.

Soft-tissue cryoablation in diffuse locations: feasibility and intermediate term outcomes.

Littrup PJ, Bang HJ, Currier BP, Goodrich DJ, Aoun HD, Heilbrun LK, Adam BA.

J Vasc Interv Radiol. 2013 Dec;24(12):1817-25. doi: 10.1016/j.jvir.2013.06.025. Epub 2013 Sep 20.

32.

Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.

Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M, Smith D, Heilbrun LK, Shi D, Sakr W, Cher ML, Chinni SR.

Mol Cancer Res. 2013 Nov;11(11):1349-61. doi: 10.1158/1541-7786.MCR-12-0705. Epub 2013 Aug 5.

33.

Galectin-3: a possible complementary marker to the PSA blood test.

Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, Heilbrun L, Raz A, Heath E.

Oncotarget. 2013 Apr;4(4):542-9.

34.

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.

Vaishampayan UN, Fontana J, Heilbrun LK, Smith D, Heath E, Dickow B, Figg WD.

Urol Oncol. 2014 Jan;32(1):31.e25-33. doi: 10.1016/j.urolonc.2012.11.017. Epub 2013 Feb 21.

35.

Effects of the oxygenation level on formation of different reactive oxygen species during photodynamic therapy.

Price M, Heilbrun L, Kessel D.

Photochem Photobiol. 2013 May-Jun;89(3):683-6. doi: 10.1111/php.12027. Epub 2013 Jan 25.

36.

Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma.

Almhanna K, El-Rayes B, Sethi S, Dyson G, Heilbrun L, Philip PA, Sarkar F.

Anticancer Res. 2012 Aug;32(8):3559-63.

37.

Acetaminophen, pesticide, and diethylhexyl phthalate metabolites, anandamide, and fatty acids in deciduous molars: potential biomarkers of perinatal exposure.

Camann DE, Schultz ST, Yau AY, Heilbrun LP, Zuniga MM, Palmer RF, Miller CS.

J Expo Sci Environ Epidemiol. 2013 Mar;23(2):190-6. doi: 10.1038/jes.2012.71. Epub 2012 Jul 18.

PMID:
22805989
38.

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer.

Ogita S, Tejwani S, Heilbrun L, Fontana J, Heath E, Freeman S, Smith D, Baranowski K, Vaishampayan U.

ISRN Oncol. 2012;2012:242850. doi: 10.5402/2012/242850. Epub 2012 Jun 13.

39.

Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.

Kafri Z, Heilbrun LK, Sukari A, Yoo G, Jacobs J, Lin HS, Mulrenan H, Smith D, Kucuk O.

ISRN Oncol. 2012;2012:159568. doi: 10.5402/2012/159568. Epub 2012 May 10.

40.

Percutaneous cryoablation of metastatic lesions from non-small-cell lung carcinoma: initial survival, local control, and cost observations.

Bang HJ, Littrup PJ, Currier BP, Goodrich DJ, Aoun HD, Klein LC, Kuo JC, Heilbrun LK, Gadgeel S, Goodman AC.

J Vasc Interv Radiol. 2012 Jun;23(6):761-9. doi: 10.1016/j.jvir.2012.02.013.

41.

Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation.

Bang HJ, Littrup PJ, Goodrich DJ, Currier BP, Aoun HD, Heilbrun LK, Vaishampayan U, Adam B, Goodman AC.

J Vasc Interv Radiol. 2012 Jun;23(6):770-7. doi: 10.1016/j.jvir.2012.03.002. Epub 2012 Apr 25.

42.

Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.

Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M, Sarkar FH.

PLoS One. 2012;7(3):e33729. doi: 10.1371/journal.pone.0033729. Epub 2012 Mar 19.

43.

Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.

Kong D, Heath E, Chen W, Cher M, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M, Sarkar FH.

Am J Transl Res. 2012;4(1):14-23. Epub 2012 Jan 5. Erratum in: Am J Transl Res. 2013 Dec 01;6(1):102-103.

44.

Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations.

Bang HJ, Littrup PJ, Currier BP, Goodrich DJ, Choi M, Heilbrun LK, Goodman AC.

ISRN Minim Invasive Surg. 2012;2012. pii: 942364.

45.

Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction.

Gupta S, Parsa V, Heilbrun LK, Smith DW, Dickow B, Heath E, Vaishampayan U.

Anticancer Drugs. 2011 Sep;22(8):794-800. doi: 10.1097/CAD.0b013e328346af0d.

46.

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.

Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P.

Clin Cancer Res. 2011 Sep 15;17(18):6052-60. doi: 10.1158/1078-0432.CCR-10-2979. Epub 2011 Jul 12.

47.
48.

Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experience.

Zafar SF, Heilbrun LK, Vishnu P, Jasti P, Venkatramanamoorthy R, Ding L, Lorusso PM, Heath EI.

J Geriatr Oncol. 2011 Jan 1;2(1):18-24.

49.

Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation.

Chopra T, Chandrasekar P, Salimnia H, Heilbrun LK, Smith D, Alangaden GJ.

Clin Transplant. 2011 Jan-Feb;25(1):E82-7. doi: 10.1111/j.1399-0012.2010.01331.x. Epub 2010 Oct 25.

50.

A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer.

Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P, Sarkar FH.

Am J Transl Res. 2010 Jul 23;2(4):402-11.

Supplemental Content

Loading ...
Support Center